<DOC>
	<DOCNO>NCT00002902</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness irinotecan plus ICI D1694 treat patient advance solid tumor .</brief_summary>
	<brief_title>Irinotecan Plus ICI D1694 Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ICI D1694 ( TDX ) give irinotecan ( CPT-11 ) every 3 week patient advance solid malignancy . II . Describe pharmacokinetics TDX CPT-11 give combination . III . Investigate relationship topoisomerase I expression peripheral mononuclear cell myelosuppression and/or gastrointestinal toxicity . IV . Investigate effect CPT-11 thymidylate synthase expression tumor . OUTLINE : This dose-escalating study determine maximum tolerate dose ( MTD ) ICI D1694 ( TDX ) give combination irinotecan . Irinotecan give intravenously day 1 ICI D1694 intravenously day 2 . Treatment repeat every 3 week disease progression unacceptable toxicity intervenes . Cohorts 3-6 patient receive escalate dos TDX MTD define ; additional 10-12 patient enter MTD confirm recommend phase II dose . PROJECTED ACCRUAL : 30-35 patient enter .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor effective therapy exist Measurable evaluable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 0 1 Hematopoietic : WBC least 3,000 AGC least 1,500 Platelets least 100,000 Hepatic : Bilirubin great 1.5 mg/dL AST/ALT great 5 time normal Renal : Creatinine great 1.5 mg/dL Metabolic : Glucose great 200 mg/dL Electrolytes within 10 % normal Other : No active infection contraindicates entry No significant medical problem contraindicates entry Effective contraception require fertile patient Able willing participate pharmacokinetic sample PRIOR CONCURRENT THERAPY : At least 3 week since chemotherapy ( 6 week since mitomycin nitrosoureas ) recover At least 3 week since radiotherapy recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2002</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>